{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:39:45Z","timestamp":1760834385477,"version":"build-2065373602"},"reference-count":26,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,12,18]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The high placebo response in depression treatment trials is a major contributing factor for randomised control trial failure to establish efficacy of novel or repurposed treatments in treatment-resistant depression (TRD) and major depressive disorder in general. Though there have been a number of meta-analyses and primary research studies evaluating the placebo response in non-TRD, placebo response in TRD is poorly understood. It is important to understand the placebo response of TRD as treatments are only moderately effective and up to 1\/3 of patients will experience TRD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will conduct a search of electronic databases (MEDLINE and PsychINFO) from inception to 24th January 2020 including randomised, placebo-controlled trials of pharmacological, somatic and psychological interventions for adults with TRD. TRD will be defined as a failure to respond to at least two interventions of adequate dose or duration. We will also search reference lists from review articles. We will perform several meta-analyses to quantify the placebo response for each treatment modality. Regression analysis will explore potential contributing demographic and clinical variables to the placebo response. We will use Cochrane risk of bias tool.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>There is no research ethics board approval required. The dissemination plan is to publish results in a peer-reviewed academic journal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>190\u2009465.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-041349","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T21:25:49Z","timestamp":1613510749000},"page":"e041349","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Protocol for a systematic review and meta-analysis of the placebo response in treatment-resistant depression: comparison of multiple treatment modalities"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-1059","authenticated-orcid":false,"given":"Brett D M","family":"Jones","sequence":"first","affiliation":[{"name":"Psychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory R","family":"Weissman","sequence":"additional","affiliation":[{"name":"Psychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lais B","family":"Razza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil"},{"name":"Laboratory of Neurosciences (LIM-27), Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Department and Institute of Psychiatry, Faculdade de Medicina, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Ishrat","family":"Husain","sequence":"additional","affiliation":[{"name":"Psychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre R","family":"Brunoni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil"},{"name":"Laboratory of Neurosciences (LIM-27), Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Department and Institute of Psychiatry, Faculdade de Medicina, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafiris J","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Psychiatry, University of California San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"2025101813201037000_11.2.e041349.1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1570159X13666150630174343","article-title":"From randomized controlled trials of antidepressant drugs to the meta-analytic synthesis of evidence: methodological aspects lead to discrepant findings","volume":"13","author":"Fountoulakis","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"2025101813201037000_11.2.e041349.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.14.1840"},{"key":"2025101813201037000_11.2.e041349.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00151.x"},{"key":"2025101813201037000_11.2.e041349.4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04516blu"},{"key":"2025101813201037000_11.2.e041349.5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4088\/JCP.11r06978","article-title":"Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation\/combination strategies in treatment partial responders\/nonresponders with major depressive disorder?","volume":"73","author":"Iovieno","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2025101813201037000_11.2.e041349.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300059"},{"key":"2025101813201037000_11.2.e041349.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00271.x"},{"key":"2025101813201037000_11.2.e041349.8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4088\/JCP.12r08267","article-title":"Less is more in antidepressant clinical trials","volume":"74","author":"Rutherford","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"2025101813201037000_11.2.e041349.9","first-page":"12","article-title":"Is high placebo response really a problem in depression trials? A critical Re-analysis of depression studies","volume":"16","author":"Whitlock","year":"2019","journal-title":"Innov Clin Neurosci"},{"key":"2025101813201037000_11.2.e041349.10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpsychires.2019.11.014","article-title":"Early score fluctuation and placebo response in a study of major depressive disorder","volume":"121","author":"Targum","year":"2020","journal-title":"J Psychiatr Res"},{"key":"2025101813201037000_11.2.e041349.11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2025101813201037000_11.2.e041349.12","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923080-00001"},{"key":"2025101813201037000_11.2.e041349.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.06.045"},{"key":"2025101813201037000_11.2.e041349.14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pnpbp.2017.10.016","article-title":"A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials","volume":"81","author":"Razza","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2025101813201037000_11.2.e041349.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004824"},{"key":"2025101813201037000_11.2.e041349.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025101813201037000_11.2.e041349.17","unstructured":"WHO . The ICD-10 classification of mental and behavioural disorders clinical descriptions and diagnostic guidelines. Available: http:\/\/www.who.int\/classifications\/icd\/en\/bluebook.pdf"},{"key":"2025101813201037000_11.2.e041349.18","doi-asserted-by":"crossref","unstructured":"First M , Gibbon M , Spitzer R . User guide for the structural clinical interview for DSM-IV axis I disorders. Washington, DC: American Psychiatric Association, 1996.","DOI":"10.1037\/t07827-000"},{"key":"2025101813201037000_11.2.e041349.19","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association, 1994."},{"key":"2025101813201037000_11.2.e041349.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.08.010"},{"key":"2025101813201037000_11.2.e041349.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(98)00004-2"},{"key":"2025101813201037000_11.2.e041349.22","unstructured":"NICE . Depression in adults (update) depression: the treatment and management of depression in adults national clinical practice guideline number X national collaborating centre for mental health commissioned by the National Institute for health and clinical Exc, 2007."},{"key":"2025101813201037000_11.2.e041349.23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088441"},{"key":"2025101813201037000_11.2.e041349.24","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000078"},{"key":"2025101813201037000_11.2.e041349.25","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04728"},{"key":"2025101813201037000_11.2.e041349.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-041349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:20:20Z","timestamp":1760818820000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-041349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,16]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-041349"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-041349","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}